Which potential side effect would the nurse include when teaching patient about the administration of ferrous gluconate?

Try the new Google Books

Check out the new look and enjoy easier access to your favorite features

luisvaschetto luisvaschetto

The phenomenon that occurs when a stimulus shifts the potential inside a neuron from the resting potential to a more negative potential is ​hyperpolarization.

What is ​hyperpolarization?

Hyperpolarization is a cellular phenomena where the cell's membrane potential becomes negative, thereby repressing the membrane's action potential.

In conclusion, the phenomenon that occurs when a stimulus shifts the potential inside a neuron from the resting potential to a more negative potential is ​hyperpolarization.

Learn more about ​hyperpolarization here:

https://brainly.com/question/12982897

#SPJ1

1. de Benoist B, cLean E, Egli I, Cogswell M, editors. WHO Global Database on Anaemia. Geneva, Switzerland: World Health Organization; 2008. [Google Scholar]

2. Kassebaum NJ, Jasrasaria R, Naghavi M et al. A systematic analysis of global anemia burden from 1990 to 2010. Blood. 2014;123(5):615–624. [PMC free article] [PubMed] [Google Scholar]

3. Guralnik JM, Eisenstaedt RS, Ferrucci L, Klein HG, Woodman RC. Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia. Blood. 2004;104(8):2263–2268. [PubMed] [Google Scholar]

4. Nissenson AR, Wade S, Goodnough T, Knight K, Dubois RW. Economic burden of anemia in an insured population. J Manag Care Pharm. 2005;11(7):565–574. [PubMed] [Google Scholar]

5. Haas JD, Brownlie T. Iron deficiency and reduced work capacity: a critical review of the research to determine a causal relationship. J Nutr. (4th) 2001;131(2S-2):676S–688S. discussion 688S-690S. [PubMed] [Google Scholar]

6. Allen RP, Auerbach S, Bahrain H, Auerbach M, Earley CJ. The prevalence and impact of restless legs syndrome on patients with iron deficiency anemia. Am J Hematol. 2013;88(4):261–264. [PubMed] [Google Scholar]

7. Wang J, O’Reilly B, Venkataraman R, Mysliwiec V, Mysliwiec A. Efficacy of oral iron in patients with restless legs syndrome and a low-normal ferritin: a randomized, double-blind, placebo-controlled study. Sleep Med. 2009;10(9):973–975. [PubMed] [Google Scholar]

8. Anker SD, Comin Colet J, Filippatos G et al. FAIR-HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361(25):2436–2448. [PubMed] [Google Scholar]

9. Wells CW, Lewis S, Barton JR, Corbett S. Effects of changes in hemoglobin level on quality of life and cognitive function in inflammatory bowel disease patients. Inflamm Bowel Dis. 2006;12(2):123–130. [PubMed] [Google Scholar]

10. Evstatiev R, Marteau P, Iqbal T et al. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology. 2011;141(3):846–853. e1-2. [PubMed] [Google Scholar]

11. Seid MH, Dahl NV, Lau G, Bernard K, Strauss W. Effect of ferumoxytol on quality of life in iron deficiency anemia from abnormal uterine bleeding. Obstet Gynecol. 2014;123(5):181S–182S. [Google Scholar]

12. Comin-Colet J, Lainscak M, Dickstein K, et al. The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study. Eur Heart J. 2013;34(1):30–38. [PMC free article] [PubMed] [Google Scholar]

13. Ponikowski P, van Veldhuisen DJ, Comin-Colet J et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J. 2015;36(11):657–668. [PMC free article] [PubMed] [Google Scholar]

14. Avni T, Leibovici L, Gafter-Gvili A. Iron supplementation for the treatment of chronic heart failure and iron deficiency: systematic review and meta-analysis. Eur J Heart Fail. 2012;14(4):423–429. [PubMed] [Google Scholar]

15. Favrat B, Balck K, Breymann C et al. Evaluation of a single dose of ferric carboxymaltose in fatigued, iron-deficient women—PREFER a randomized, placebo-controlled study. PLoS One. 2014;9(4) e94217. [PMC free article] [PubMed] [Google Scholar]

16. Verdon F, Burnand B, Stubi CL et al. Iron supplementation for unexplained fatigue in non-anaemic women: double blind randomised placebo controlled trial. BMJ. 2003;326(7399):1124. [PMC free article] [PubMed] [Google Scholar]

17. Krayenbuehl PA, Battegay E, Breymann C, Furrer J, Schulthess G. Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration. Blood. 2011;118(12):3222–3227. [PubMed] [Google Scholar]

18. Bruner AB, Joffe A, Duggan AK, Casella JF, Brandt J. Randomised study of cognitive effects of iron supplementation in non-anaemic iron-deficient adolescent girls. Lancet. 1996;348(9033):992–996. [PubMed] [Google Scholar]

19. Lozoff B, Jimenez E, Smith JB. Double burden of iron deficiency in infancy and low socioeconomic status: a longitudinal analysis of cognitive test scores to age 19 years. Arch Pediatr Adolesc Med. 2006;160(11):1108–1113. [PMC free article] [PubMed] [Google Scholar]

20. Falkingham M, Abdelhamid A, Curtis P, Fairweather-Tait S, Dye L, Hooper L. The effects of oral iron supplementation on cognition in older children and adults: a systematic review and meta-analysis. Nutr J. 2010;9(1):4. [PMC free article] [PubMed] [Google Scholar]

21. Chavarro JE, Rich-Edwards JW, Rosner BA, Willett WC. Iron intake and risk of ovulatory infertility. Obstet Gynecol. 2006;108(5):1145–1152. [PubMed] [Google Scholar]

22. Hershko C, Hoffbrand AV, Keret D et al. Role of autoimmune gastritis, Helicobacter pylori and celiac disease in refractory or unexplained iron deficiency anemia. Haematologica. 2005;90(5):585–595. [PubMed] [Google Scholar]

23. Corazza GR, Valentini RA, Andreani ML et al. Subclinical coeliac disease is a frequent cause of iron-deficiency anaemia. Scand J Gastroenterol. 1995;30(2):153–156. [PubMed] [Google Scholar]

24. Kulnigg S, Gasche C. Systematic review: managing anaemia in Crohn’s disease. Aliment Pharmacol Ther. 2006;24(11-12):1507–1523. [PubMed] [Google Scholar]

25. Gasche C. Anemia in IBD: the overlooked villain. Inflamm Bowel Dis. 2000;6(2):142–150. [PubMed] [Google Scholar]

26. De Nicola L, Minutolo R, Chiodini P et al. SIN-TABLE CDK Study Group. Prevalence and prognosis of mild anemia in non-dialysis chronic kidney disease: a prospective cohort study in outpatient renal clinics. Am J Nephrol. 2010;32(6):533–540. [PubMed] [Google Scholar]

27. Minutolo R, Locatelli F, Gallieni M et al. REport of COmorbidities in non-Dialysis Renal Disease Population in Italy (RECORD-IT) Study Group. Anaemia management in non-dialysis chronic kidney disease (CKD) patients: a multicentre prospective study in renal clinics. Nephrol Dial Transplant. 2013;28(12):3035–3045. [PubMed] [Google Scholar]

28. Baribeault D, Auerbach M. Iron replacement therapy in cancer-related anemia. Am J Health Syst Pharm. 2011;68(10) suppl 1:S4–S14. quiz S15-S16. [PubMed] [Google Scholar]

29. Jankowska EA, Rozentryt P, Witkowska A et al. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J. 2010;31(15):1872–1880. [PubMed] [Google Scholar]

30. Klip IT, Comin-Colet J, Voors AA et al. Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J. 2013;165(4):575–582. e3. [PubMed] [Google Scholar]

31. Dan K. Thrombocytosis in iron deficiency anemia. Intern Med. 2005;44(10):1025–1026. [PubMed] [Google Scholar]

32. Kadikoylu G, Yavasoglu I, Bolaman Z, Senturk T. Platelet parameters in women with iron deficiency anemia. J Natl Med Assoc. 2006;98(3):398–402. [PMC free article] [PubMed] [Google Scholar]

33. Park MJ, Park PW, Seo YH et al. The relationship between iron parameters and platelet parameters in women with iron deficiency anemia and thrombocytosis. Platelets. 2013;24(5):348–351. [PubMed] [Google Scholar]

34. Keung YK, Owen J. Iron deficiency and thrombosis: literature review. Clin Appl Thromb Hemost. 2004;10(4):387–391. [PubMed] [Google Scholar]

35. Chang YL, Hung SH, Ling W, Lin HC, Li HC, Chung SD. Association between ischemic stroke and iron-deficiency anemia: a population-based study. PLoS One. 2013;8(12) e82952. [PMC free article] [PubMed] [Google Scholar]

36. Maguire JL, deVeber G, Parkin PC. Association between iron-deficiency anemia and stroke in young children. Pediatrics. 2007;120(5):1053–1057. [PubMed] [Google Scholar]

37. Azab SF, Abdelsalam SM, Saleh SH et al. Iron deficiency anemia as a risk factor for cerebrovascular events in early childhood: a case-control study. Ann Hematol. 2014;93(4):571–576. [PubMed] [Google Scholar]

38. Gillum RF, Sempos CT, Makuc DM, Looker AC, Chien CY, Ingram DD. Serum transferrin saturation, stroke incidence, and mortality in women and men. The NHANES I Epidemiologic Followup Study. National Health and Nutrition Examination Survey. Am J Epidemiol. 1996;144(1):59–68. [PubMed] [Google Scholar]

39. Cook IJ, Pavli P, Riley JW, Goulston KJ, Dent OF. Gastrointestinal investigation of iron deficiency anaemia. Br Med J (Clin Res Ed). 1986;292(6532):1380–1382. [PMC free article] [PubMed] [Google Scholar]

40. Kepczyk T, Kadakia SC. Prospective evaluation of gastrointestinal tract in patients with iron-deficiency anemia. Dig Dis Sci. 1995;40(6):1283–1289. [PubMed] [Google Scholar]

41. Green BT, Rockey DC. Gastrointestinal endoscopic evaluation of premenopausal women with iron deficiency anemia. J Clin Gastroenterol. 2004;38(2):104–109. [PubMed] [Google Scholar]

42. Carter D, Levi G, Tzur D, Novis B, Avidan B. Prevalence and predictive factors for gastrointestinal pathology in young men evaluated for iron deficiency anemia. Dig Dis Sci. 2013;58(5):1299–1305. [PubMed] [Google Scholar]

43. Carter D, Maor Y, Bar-Meir S, Avidan B. Prevalence and predictive signs for gastrointestinal lesions in premenopausal women with iron deficiency anemia. Dig Dis Sci. 2008;53(12):3138–3144. [PubMed] [Google Scholar]

44. Goddard AF, James MW, McIntyre AS, Scott BB. British Society of Gastroenterology. Guidelines for the management of iron deficiency anaemia. Gut. 2011;60(10):1309–1316. [PubMed] [Google Scholar]

45. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352(10):1011–1023. [PubMed] [Google Scholar]

46. Evstatiev R, Gasche C. Iron sensing and signalling. Gut. 2012;61(6):933–952. [PubMed] [Google Scholar]

47. Assessing the Iron Status of Populations. 2nd ed. Geneva, Switzerland: World Health Organization; 2007. [Google Scholar]

48. Beutler E, Waalen J. The definition of anemia: what is the lower limit of normal of the blood hemoglobin concentration? Blood. 2006;107(5):1747–1750. [PMC free article] [PubMed] [Google Scholar]

49. Cook JD, Boy E, Flowers C, Daroca MC. The influence of high-altitude living on body iron. Blood. 2005;106(4):1441–1446. [PubMed] [Google Scholar]

50. Nordenberg D, Yip R, Binkin NJ. The effect of cigarette smoking on hemoglobin levels and anemia screening. JAMA. 1990;264(12):1556–1559. [PubMed] [Google Scholar]

51. Dickson DN, Wilkinson RL, Noakes TD. Effects of ultra-marathon training and racing on hematologic parameters and serum ferritin levels in well-trained athletes. Int J Sports Med. 1982;3(2):111–117. [PubMed] [Google Scholar]

52. Oustamanolakis P, Koutroubakis IE, Messaritakis I, Kefalogiannis G, Niniraki M, Kouroumalis EA. Measurement of reticulocyte and red blood cell indices in the evaluation of anemia in inflammatory bowel disease. J Crohns Colitis. 2011;5(4):295–300. [PubMed] [Google Scholar]

53. Gasche C, Berstad A, Befrits R et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis. 2007;13(12):1545–1553. [PubMed] [Google Scholar]

54. Dignass AU, Gasche C, Bettenworth D et al. European Crohn’s and Colitis Organisation [ECCO]. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohns Colitis. 2015;9(3):211–222. [PubMed] [Google Scholar]

55. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int. 2012;2012(suppl 2012):2279–2335. [Google Scholar]

56. McMurray JJ, Adamopoulos S, Anker SD et al. ESC Committee for Practice Guidelines. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33(14):1787–1847. [PubMed] [Google Scholar]

57. Beguin Y. Soluble transferrin receptor for the evaluation of erythropoiesis and iron status. Clin Chim Acta. 2003;329(1-2):9–22. [PubMed] [Google Scholar]

58. Skikne BS, Punnonen K, Caldron PH et al. Improved differential diagnosis of anemia of chronic disease and iron deficiency anemia: a prospective multicenter evaluation of soluble transferrin receptor and the sTfR/log ferritin index. Am J Hematol. 2011;86(11):923–927. [PubMed] [Google Scholar]

59. Infusino I, Braga F, Dolci A, Panteghini M. Soluble transferrin receptor (sTfR) and sTfR/log ferritin index for the diagnosis of iron-deficiency anemia. A meta-analysis. Am J Clin Pathol. 2012;138(5):642–649. [PubMed] [Google Scholar]

60. Werner E, Kaltwasser JP, Ihm P. Intestinal absorption from therapeutic iron doses (author’s transl) [in German] Arzneimittelforschung. 1976;26(11):2093–2100. [PubMed] [Google Scholar]

61. de Silva AD, Tsironi E, Feakins RM, Rampton DS. Efficacy and tolerability of oral iron therapy in inflammatory bowel disease: a prospective, comparative trial. Aliment Pharmacol Ther. 2005;22(11-12):1097–1105. [PubMed] [Google Scholar]

62. Abraham SC, Yardley JH, Wu TT. Erosive injury to the upper gastrointestinal tract in patients receiving iron medication: an underrecognized entity. Am J Surg Pathol. 1999;23(10):1241–1247. [PubMed] [Google Scholar]

63. Seril DN, Liao J, Ho KL, Warsi A, Yang CS, Yang GY. Dietary iron supplementation enhances DSS-induced colitis and associated colorectal carcinoma development in mice. Dig Dis Sci. 2002;47(6):1266–1278. [PubMed] [Google Scholar]

64. Tolkien Z, Stecher L, Mander AP, Pereira DI, Powell JJ. Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis. PLoS One. 2015;10(2) e0117383. [PMC free article] [PubMed] [Google Scholar]

65. Zhou SJ, Gibson RA, Crowther CA, Makrides M. Should we lower the dose of iron when treating anaemia in pregnancy? A randomized dose-response trial. Eur J Clin Nutr. 2009;63(2):183–190. [PubMed] [Google Scholar]

66. Makrides M, Crowther CA, Gibson RA, Gibson RS, Skeaff CM. Efficacy and tolerability of low-dose iron supplements during pregnancy: a randomized controlled trial. Am J Clin Nutr. 2003;78(1):145–153. [PubMed] [Google Scholar]

67. Rimon E, Kagansky N, Kagansky M et al. Are we giving too much iron? Low-dose iron therapy is effective in octogenarians. Am J Med. 2005;118(10):1142–1147. [PubMed] [Google Scholar]

68. Koutroubakis IE, Oustamanolakis P, Karakoidas C, Mantzaris GJ, Kouroumalis EA. Safety and efficacy of total-dose infusion of low molecular weight iron dextran for iron deficiency anemia in patients with inflammatory bowel disease. Dig Dis Sci. 2010;55(8):2327–2331. [PubMed] [Google Scholar]

69. Onken JE, Bregman DB, Harrington RA et al. A multicenter, randomized, active-controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemia. Transfusion. 2014;54(2):306–315. [PubMed] [Google Scholar]

70. Rozen-Zvi B, Gafter-Gvili A, Paul M, Leibovici L, Shpilberg O, Gafter U. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis. Am J Kidney Dis. 2008;52(5):897–906. [PubMed] [Google Scholar]

71. Lindgren S, Wikman O, Befrits R et al. Intravenous iron sucrose is superior to oral iron sulphate for correcting anaemia and restoring iron stores in IBD patients: a randomized, controlled, evaluator-blind, multicentre study. Scand J Gastroenterol. 2009;44(7):838–845. [PubMed] [Google Scholar]

72. Khalafallah A, Dennis A, Bates J et al. A prospective randomized, controlled trial of intravenous versus oral iron for moderate iron deficiency anaemia of pregnancy. J Intern Med. 2010;268(3):286–295. [PubMed] [Google Scholar]

73. Schroder O, Mickisch O, Seidler U et al. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease—a randomized, controlled, open-label, multicenter study. Am J Gastroenterol. 2005;100(11):2503–2509. [PubMed] [Google Scholar]

74. Kulnigg S, Stoinov S, Simanenkov V et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol. 2008;103(5):1182–1192. [PubMed] [Google Scholar]

75. Khalafallah AA, Dennis AE, Ogden K et al. Three-year follow-up of a randomised clinical trial of intravenous versus oral iron for anaemia in pregnancy. BMJ Open. 2012;2(5) e000998. [PMC free article] [PubMed] [Google Scholar]

76. Evstatiev R, Alexeeva O, Bokemeyer B et al. Ferric carboxymaltose prevents recurrence of anemia in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11(3):269–277. [PubMed] [Google Scholar]

77. Auerbach M, Macdougall IC. Safety of intravenous iron formulations: facts and folklore. Blood Transfus. 2014;12(3):296–300. [PMC free article] [PubMed] [Google Scholar]

78. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmén J. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant. 2006;21(2):378–382. [PubMed] [Google Scholar]

79. Hussain I, Bhoyroo J, Butcher A, Koch TA, He A, Bregman DB. Direct comparison of the safety and efficacy of ferric carboxymaltose versus iron dextran in patients with iron deficiency anemia. Anemia. 2013;2013:169107. [PMC free article] [PubMed] [Google Scholar]

80. Ganzoni AM. Intravenous iron-dextran: therapeutic and experimental possibilities [in German] Schweiz Med Wochenschr. 1970;100(7):301–303. [PubMed] [Google Scholar]

81. Reinisch W, Staun M, Tandon RK et al. A randomized, open-label, noninferiority study of intravenous iron isomaltoside 1,000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED) Am J Gastroenterol. 2013;108(12):1877–1888. [PMC free article] [PubMed] [Google Scholar]

82. Auerbach M, Pappadakis JA, Bahrain H, Auerbach SA, Ballard H, Dahl NV. Safety and efficacy of rapidly administered (one hour) one gram of low molecular weight iron dextran (INFeD) for the treatment of iron deficient anemia. Am J Hematol. 2011;86(10):860–862. [PubMed] [Google Scholar]

83. Ali M, Rigolosi R, Fayemi AO, Braun EV, Frascino J, Singer R. Failure of serum ferritin levels to predict bone-marrow iron content after intravenous iron-dextran therapy. Lancet. 1982;1(8273):652–655. [PubMed] [Google Scholar]

84. Novacek G, Weltermann A, Sobala A et al. Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism. Gastroenterology. 2010;139(3):779–787. 787.e1. [PubMed] [Google Scholar]

85. Carson JL, Grossman BJ, Kleinman S et al. Clinical Transfusion Medicine Committee of the AABB. Red blood cell transfusion: a clinical practice guideline from the AABB. Ann Intern Med. 2012;157(1):49–58. [PubMed] [Google Scholar]

86. Villanueva C, Colomo A, Bosch A et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med. 2013;368(1):11–21. [PubMed] [Google Scholar]

87. Hébert PC, Wells G, Blajchman MA et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med. 1999;340(6):409–417. [PubMed] [Google Scholar]

88. Haider BA, Olofin I, Wang M, Spiegelman D, Ezzati M, Fawzi WW. Nutrition Impact Model Study Group (anaemia). Anaemia, prenatal iron use, and risk of adverse pregnancy outcomes: systematic review and meta-analysis. BMJ. 2013;346:f3443. [PMC free article] [PubMed] [Google Scholar]

89. Rees MC. Role of menstrual blood loss measurements in management of complaints of excessive menstrual bleeding. Br J Obstet Gynaecol. 1991;98(3):327–328. [PubMed] [Google Scholar]

90. Warner PE, Critchley HO, Lumsden MA, Campbell-Brown M, Douglas A, Murray GD. Menorrhagia I: measured blood loss, clinical features, and outcome in women with heavy periods: a survey with follow-up data. Am J Obstet Gynecol. 2004;190(5):1216–1223. [PubMed] [Google Scholar]

91. Vannella L, Aloe Spiriti MA, Cozza G et al. Benefit of concomitant gastrointestinal and gynaecological evaluation in premenopausal women with iron deficiency anaemia. Aliment Pharmacol Ther. 2008;28(4):422–430. [PubMed] [Google Scholar]

92. Annibale B, Lahner E, Chistolini A et al. Endoscopic evaluation of the upper gastrointestinal tract is worthwhile in premenopausal women with iron-deficiency anaemia irrespective of menstrual flow. Scand J Gastroenterol. 2003;38(3):239–245. [PubMed] [Google Scholar]

93. Capurso G, Baccini F, Osborn J et al. Can patient characteristics predict the outcome of endoscopic evaluation of iron deficiency anemia: a multiple logistic regression analysis. Gastrointest Endosc. 2004;59(7):766–771. [PubMed] [Google Scholar]

94. James MW, Chen CM, Goddard WP, Scott BB, Goddard AF. Risk factors for gastrointestinal malignancy in patients with iron-deficiency anaemia. Eur J Gastroenterol Hepatol. 2005;17(11):1197–1203. [PubMed] [Google Scholar]

95. Hamilton W, Lancashire R, Sharp D, Peters TJ, Cheng KK, Marshall T. The importance of anaemia in diagnosing colorectal cancer: a case-control study using electronic primary care records. Br J Cancer. 2008;98(2):323–327. [PMC free article] [PubMed] [Google Scholar]

96. Ioannou GN, Rockey DC, Bryson CL, Weiss NS. Iron deficiency and gastrointestinal malignancy: a population-based cohort study. Am J Med. 2002;113(4):276–280. [PubMed] [Google Scholar]

97. Bini EJ, Micale PL, Weinshel EH. Evaluation of the gastrointestinal tract in premenopausal women with iron deficiency anemia. Am J Med. 1998;105(4):281–286. [PubMed] [Google Scholar]

98. Annibale B, Capurso G, Chistolini A et al. Gastrointestinal causes of refractory iron deficiency anemia in patients without gastrointestinal symptoms. Am J Med. 2001;111(6):439–445. [PubMed] [Google Scholar]

99. Srinivas M, Basumani P, Podmore G, Shrimpton A, Bardhan KD. Utility of testing patients, on presentation, for serologic features of celiac disease. Clin Gastroenterol Hepatol. 2014;12(6):946–952. [PubMed] [Google Scholar]

100. Kaye PV, Garsed K, Ragunath K, Jawhari A, Pick B, Atherton JC. The clinical utility and diagnostic yield of routine gastric biopsies in the investigation of iron deficiency anemia: a case-control study. Am J Gastroenterol. 2008;103(11):2883–2889. [PubMed] [Google Scholar]

101. Dickey W, Kenny BD, McMillan SA, Porter KG, McConnell JB. Gastric as well as duodenal biopsies may be useful in the investigation of iron deficiency anaemia. Scand J Gastroenterol. 1997;32(5):469–472. [PubMed] [Google Scholar]

102. Barada K, Habib RH, Malli A et al. Prediction of celiac disease at endoscopy. Endoscopy. 2014;46(2):110–119. [PubMed] [Google Scholar]

103. Robson K, Alizart M, Martin J, Nagel R. Coeliac patients are undiagnosed at routine upper endoscopy. PLoS One. 2014;9(3) e90552. [PMC free article] [PubMed] [Google Scholar]

104. Raju GS, Gerson L, Das A, Lewis B. American Gastroenterological Association. American Gastroenterological Association (AGA) Institute medical position statement on obscure gastrointestinal bleeding. Gastroenterology. 2007;133(5):1694–1696. [PubMed] [Google Scholar]

105. Bull-Henry K, Al-Kawas FH. Evaluation of occult gastrointestinal bleeding. Am Fam Physician. 2013;87(6):430–436. [PubMed] [Google Scholar]

106. Choi SI, Simone JV, Jackson CW. Megakaryocytopoiesis in experimental iron deficiency anemia. Blood. 1974;43(1):111–120. [PubMed] [Google Scholar]

107. Evstatiev R, Bukaty A, Jimenez K et al. Iron deficiency alters megakaryopoiesis and platelet phenotype independent of thrombopoietin. Am J Hematol. 2014;89(5):524–529. [PMC free article] [PubMed] [Google Scholar]

108. Akay OM, Akin E, Mutlu FS, Gulbas Z. Effect of iron therapy on platelet function among iron-deficient women with unexplained menorrhagia. Pathophysiol Haemost Thromb. 2008;36(2):80–83. [PubMed] [Google Scholar]

109. Woods HF, Youdim MB, Boullin D, Callender S. Monoamine metabolism and platelet function in iron-deficiency anaemia. Ciba Found Symp. 1976;(51):227–248. [PubMed] [Google Scholar]

110. Shovlin CL, Chamali B, Santhirapala V et al. Ischaemic strokes in patients with pulmonary arteriovenous malformations and hereditary hemorrhagic telangiectasia: associations with iron deficiency and platelets. PLoS One. 2014;9(2) e88812. [PMC free article] [PubMed] [Google Scholar]

111. Khorana AA, Francis CW, Culakova E, Lyman GH. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer. 2005;104(12):2822–2829. [PubMed] [Google Scholar]

112. Simanek R, Vormittag R, Ay C et al. High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS) J Thromb Haemost. 2010;8(1):114–120. [PubMed] [Google Scholar]

113. Danese S, Papa A, Saibeni S, Repici A, Malesci A, Vecchi M. Inflammation and coagulation in inflammatory bowel disease: the clot thickens. Am J Gastroenterol. 2007;102(1):174–186. [PubMed] [Google Scholar]

114. Edwards RL, Rickles FR, Moritz TE et al. Abnormalities of blood coagulation tests in patients with cancer. Am J Clin Pathol. 1987;88(5):596–602. [PubMed] [Google Scholar]

115. Danese S, de la Motte C, Fiocchi C. Platelets in inflammatory bowel disease: clinical, pathogenic, and therapeutic implications. Am J Gastroenterol. 2004;99(5):938–945. [PubMed] [Google Scholar]

116. Voudoukis E, Karmiris K, Oustamanolakis P et al. Association between thrombocytosis and iron deficiency anemia in inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2013;25(10):1212–1216. [PubMed] [Google Scholar]

117. Kulnigg-Dabsch S, Evstatiev R, Dejaco C, Gasche C. Effect of iron therapy on platelet counts in patients with inflammatory bowel disease-associated anemia. PLoS One. 2012;7(4) e34520. [PMC free article] [PubMed] [Google Scholar]

118. Kulnigg-Dabsch S, Schmid W, Howaldt S et al. Iron deficiency generates secondary thrombocytosis and platelet activation in IBD: the randomized, controlled thromboVIT trial. Inflamm Bowel Dis. 2013;19(8):1609–1616. [PubMed] [Google Scholar]

119. Yessayan L, Yee J, Zasuwa G, Frinak S, Besarab A. Iron repletion is associated with reduction in platelet counts in non-dialysis chronic kidney disease patients independent of erythropoiesis-stimulating agent use: a retrospective cohort study. BMC Nephrol. 2014;15(1):119. [PMC free article] [PubMed] [Google Scholar]

120. Henry DH, Dahl NV, Auerbach MA. Thrombocytosis and venous thrombo-embolism in cancer patients with chemotherapy induced anemia may be related to ESA induced iron restricted erythropoiesis and reversed by administration of IV iron. Am J Hematol. 2012;87(3):308–310. [PubMed] [Google Scholar]

121. Koskenkorva-Frank TS, Weiss G, Koppenol WH, Burckhardt S. The complex interplay of iron metabolism, reactive oxygen species, and reactive nitrogen species: insights into the potential of various iron therapies to induce oxidative and nitrosative stress. Free Radic Biol Med. 2013;65:1174–1194. [PubMed] [Google Scholar]

122. Stevens RG, Jones DY, Micozzi MS, Taylor PR. Body iron stores and the risk of cancer. N Engl J Med. 1988;319(16):1047–1052. [PubMed] [Google Scholar]

123. Stevens RG, Graubard BI, Micozzi MS, Neriishi K, Blumberg BS. Moderate elevation of body iron level and increased risk of cancer occurrence and death. Int J Cancer. 1994;56(3):364–369. [PubMed] [Google Scholar]

124. Mainous AG, III, Gill JM, Everett CJ. Transferrin saturation, dietary iron intake, and risk of cancer. Ann Fam Med. 2005;3(2):131–137. [PMC free article] [PubMed] [Google Scholar]

125. Gaur A, Collins H, Wulaningsih W et al. Iron metabolism and risk of cancer in the Swedish AMORIS study. Cancer Causes Control. 2013;24(7):1393–1402. [PMC free article] [PubMed] [Google Scholar]

126. Nelson RL. Iron and colorectal cancer risk: human studies. Nutr Rev. 2001;59(5):140–148. [PubMed] [Google Scholar]

127. Norat T, Bingham S, Ferrari P et al. Meat, fish, and colorectal cancer risk: the European Prospective Investigation into cancer and nutrition. J Natl Cancer Inst. 2005;97(12):906–916. [PMC free article] [PubMed] [Google Scholar]

128. Kabat GC, Miller AB, Jain M, Rohan TE. A cohort study of dietary iron and heme iron intake and risk of colorectal cancer in women. Br J Cancer. 2007;97(1):118–122. [PMC free article] [PubMed] [Google Scholar]

129. Kato I, Dnistrian AM, Schwartz M et al. Iron intake, body iron stores and colorectal cancer risk in women: a nested case-control study. Int J Cancer. 1999;80(5):693–698. [PubMed] [Google Scholar]

130. Beguin Y, Aapro M, Ludwig H, Mizzen L, Osterborg A. Epidemiological and nonclinical studies investigating effects of iron in carcinogenesis—a critical review. Crit Rev Oncol Hematol. 2014;89(1):1–15. [PubMed] [Google Scholar]

Page 2

Causes of Iron Deficiency